Spark Therapeutics
NEWS
As the city rapidly develops as a biopharma hub, wet lab space is rapidly dwindling.
The startup’s initial focus will be on rare blindness conditions affecting pediatric patients.
The collaboration between Spark and NeuExcell increased the hope for Huntington’s disease cure in near future. This is going to be a great relief for all the patients.
The oncogenicity and neurotoxicity risks of AAVs and possible mitigation strategies were the primary focus on Thursday.
bluebird bio is hitting back at Spark Therapeutics over the use of the word “spark” involving the company’s “Be the Spark” campaign against sickle cell disease.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
It was a busy week for clinical trial updates. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Dyno will be responsible for the design of the novel AAV capsids that are expected to have improved functional properties for gene therapy. Roche and its subsidiary Spark Therapeutics will take the capsids and conduct preclinical studies with hopes of taking them into the clinic, and eventually to commercialization.
JOBS
IN THE PRESS